Fibromyalgia Trial, Recruiting NCT06746922 Sponsor: Izmir Katip Celebi University Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT06746922
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You have been diagnosed with fibromyalgia syndrome (based on 2016 diagnostic criteria)
  • Your average pain level is at least 4 out of 10 on a pain scale
  • Your fibromyalgia treatment has stayed the same for the past 3 months and you are not planning to change it during the study

Who may not be able to join:

  • You have any condition that makes a brain stimulation treatment called TMS unsafe for you, such as metal implants in your body, a heart pacemaker, epilepsy, or a history of brain surgery (confirm with trial site)
  • You have or have had cancer
  • You have a rheumatic disease affecting your whole body (such as lupus or rheumatoid arthritis)
  • You have a serious bone or joint problem that limits your everyday movement, such as difficulty walking, limited joint mobility from a past fracture, a prosthetic limb, or nerve/tendon injuries
  • You have a serious neurological (brain or nerve) condition, such as Parkinson's disease, multiple sclerosis, a history of epilepsy, a brain aneurysm, or a past head injury that caused loss of consciousness
  • You have an addiction to alcohol or drugs
  • You have a history of major depression, a personality disorder, or psychosis
  • You have previously received TMS (brain stimulation) treatment
  • You are currently taking, or have taken in the last 4 weeks, certain medications such as benzodiazepines, gabapentin, pregabalin, or anti-seizure drugs that could interfere with the treatment (confirm with trial site)
  • You are currently pregnant, planning to become pregnant, or breastfeeding

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 902322444444

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Izmir Katip Celebi University
Registry
ClinicalTrials.gov
Start date
13 March 2025
Est. completion
1 February 2027

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Change from baseline in the Numeric Rating Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov